- Home
- LFLYW vs TGTX Comparison
LFLYW vs TGTX Comparison
Compare LFLYW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFLYW
- TGTX
- Stock Information
- Founded
- LFLYW N/A
- TGTX 1993
- Country
- LFLYW United States
- TGTX United States
- Employees
- LFLYW 131
- TGTX N/A
- Industry
- LFLYW Computer Software: Prepackaged Software
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- LFLYW Technology
- TGTX Health Care
- Exchange
- LFLYW Nasdaq
- TGTX Nasdaq
- Market Cap
- LFLYW N/A
- TGTX 3.6B
- IPO Year
- LFLYW 2019
- TGTX 1995
- Fundamental
- Price
- LFLYW $0.02
- TGTX $22.03
- Analyst Decision
- LFLYW
- TGTX Strong Buy
- Analyst Count
- LFLYW 0
- TGTX 6
- Target Price
- LFLYW N/A
- TGTX $33.60
- AVG Volume (30 Days)
- LFLYW N/A
- TGTX 3.2M
- Earning Date
- LFLYW N/A
- TGTX 10-30-2024
- Dividend Yield
- LFLYW N/A
- TGTX N/A
- EPS Growth
- LFLYW N/A
- TGTX N/A
- EPS
- LFLYW N/A
- TGTX 0.64
- Revenue
- LFLYW N/A
- TGTX $346,724,000.00
- Revenue This Year
- LFLYW N/A
- TGTX $43.34
- Revenue Next Year
- LFLYW N/A
- TGTX $50.79
- P/E Ratio
- LFLYW N/A
- TGTX $34.47
- Revenue Growth
- LFLYW N/A
- TGTX 1341.56
- 52 Week Low
- LFLYW N/A
- TGTX $6.46
- 52 Week High
- LFLYW N/A
- TGTX $25.70
- Technical
- Relative Strength Index (RSI)
- LFLYW N/A
- TGTX 49.61
- Support Level
- LFLYW N/A
- TGTX $22.90
- Resistance Level
- LFLYW N/A
- TGTX $25.70
- Average True Range (ATR)
- LFLYW 0.00
- TGTX 1.31
- MACD
- LFLYW 0.00
- TGTX -0.33
- Stochastic Oscillator
- LFLYW 0.00
- TGTX 20.04
About LFLYW Leafly Holdings Inc. Warrant
Leafly Holdings Inc operates an online cannabis information resource platform. It offers cannabis retailers and brands subscription-based marketplace listings that provide its cannabis audience with information, reviews, menus, and ordering and delivery options through legal retailers.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.